CMS Issues Coverage Guidance on GLP-1 Anti-Obesity Drugs: Implications for Health Plans Posted on April 5, 2024 CMS Issued Coverage Guidance on GLP-1 Anti-Obesity Drugs Requiring Considerations for Health Plans GLP-1s (glucagon-like peptide 1 agonist) came up in the news again after the Centers for Medicare and Medicaid Services (CMS) issued coverage guidance on GLP-1 anti-obesity drugs with expanded indications on March 20, 2024.* Since the inception of Medicare Part D, drugs used for weight loss have been excluded from basic coverage
At Fitty, this understanding shapes everything we do
The Colca Canyon is home to impressive giant birds such as the Andean condor and it is the best place to witness the Flight of the Condor, it is from the Mirador de la Cruz del Cndor, in this place visitors will be able to appreciate it up close
doi: 10.1016/S0140-6736(21)01324-6 Summary Keywords glucagon, GLP-1, obesity, co-agonist, weight loss Citation Hope DCD, Vincent ML and Tan TMM (2021) Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity
